TY - JOUR
T1 - Management of anaemia and iron deficiency in patients with cancer
T2 - ESMO Clinical Practice Guidelines
AU - ESMO Guidelines Committee
AU - Aapro, M.
AU - Beguin, Y.
AU - Bokemeyer, C.
AU - Dicato, M.
AU - Gascón, P.
AU - Glaspy, J.
AU - Hofmann, A.
AU - Link, H.
AU - Littlewood, T.
AU - Ludwig, H.
AU - Österborg, A.
AU - Pronzato, P.
AU - Santini, V.
AU - Schrijvers, D.
AU - Stauder, R.
AU - Jordan, K.
AU - Herrstedt, J.
PY - 2018/10/1
Y1 - 2018/10/1
N2 - Ann Oncol 2018; 29: iv96-iv110 (doi:10.1093/annonc/mdx758) The following corrections have been made: In "Table 2. Managing anaemia in patients with MDS" In the last sentence, the word: patient has been replaced with: patients In "Table 4. Approved ESAs and i.v. iron compounds and their approved dosing in patients with solid tumours and haematological malignanciesa,b" For iron isomaltoside, maximum infusion dose, a new footnote 'e' has been added: eThe authors suggest a dose up to 1000 mg, while drug labels might allow more. For iron isomaltoside, minimum infusion time: 60 min Has been replaced with: 15 minf For iron isomaltoside, minimum infusion time, a new footnote 'f' has been added: fIf dose is up to 1000 mg; if dose exceeds 1000 mg iron, more than 30 min is recommended, as per label. In Figure 2: "Management of chemotherapy-induced anaemia in patients with very low to intermediate-risk MDS" The title has been replaced with: Management of anaemia in patients with very low to intermediate-risk MDS Under the section "Conclusions" MDS patients with low to intermediate-1 risk (IPSS) or very low to intermediate risk (revised; IPSS-R) disease and symptomatic anaemia should be considered for ESA therapy, despite the fact that ESAs are currently not EMA-approved for use in patients withMDS [I, A]. Has been replaced with: MDS patients with low to intermediate-1 risk (IPSS) or very low to intermediate risk (revised; IPSS-R) disease and symptomatic anaemia should be considered for ESA therapy, despite the fact that not all ESAs are currentlyEMA-approved for use in patients withMDS [I, A].
AB - Ann Oncol 2018; 29: iv96-iv110 (doi:10.1093/annonc/mdx758) The following corrections have been made: In "Table 2. Managing anaemia in patients with MDS" In the last sentence, the word: patient has been replaced with: patients In "Table 4. Approved ESAs and i.v. iron compounds and their approved dosing in patients with solid tumours and haematological malignanciesa,b" For iron isomaltoside, maximum infusion dose, a new footnote 'e' has been added: eThe authors suggest a dose up to 1000 mg, while drug labels might allow more. For iron isomaltoside, minimum infusion time: 60 min Has been replaced with: 15 minf For iron isomaltoside, minimum infusion time, a new footnote 'f' has been added: fIf dose is up to 1000 mg; if dose exceeds 1000 mg iron, more than 30 min is recommended, as per label. In Figure 2: "Management of chemotherapy-induced anaemia in patients with very low to intermediate-risk MDS" The title has been replaced with: Management of anaemia in patients with very low to intermediate-risk MDS Under the section "Conclusions" MDS patients with low to intermediate-1 risk (IPSS) or very low to intermediate risk (revised; IPSS-R) disease and symptomatic anaemia should be considered for ESA therapy, despite the fact that ESAs are currently not EMA-approved for use in patients withMDS [I, A]. Has been replaced with: MDS patients with low to intermediate-1 risk (IPSS) or very low to intermediate risk (revised; IPSS-R) disease and symptomatic anaemia should be considered for ESA therapy, despite the fact that not all ESAs are currentlyEMA-approved for use in patients withMDS [I, A].
UR - http://www.scopus.com/inward/record.url?scp=85054405265&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054405265&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdy323
DO - 10.1093/annonc/mdy323
M3 - Article
C2 - 30285221
AN - SCOPUS:85054405265
VL - 29
SP - iv271
JO - Annals of Oncology
JF - Annals of Oncology
SN - 0923-7534
IS - 4
ER -